Reuters logo
BRIEF-Advaxis says 38 pct of patients with heavily pretreated prmcc were alive 12 months following treatment with axalimogene filolisbac
2017年3月15日 / 中午11点34分 / 8 个月前

BRIEF-Advaxis says 38 pct of patients with heavily pretreated prmcc were alive 12 months following treatment with axalimogene filolisbac

March 15 (Reuters) - Advaxis Inc

* Advaxis presents oral late-breaking data on phase 2 gog-0265 study of axalimogene filolisbac

* Advaxis - final efficacy results of gog-0265 demonstrated 38% of patients with heavily pretreated prmcc were alive 12 months following treatment with axalimogene filolisbac

* Advaxis inc - safety profile was consistent with previous clinical experience Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below